<= 1 / 20=>
1.
Mechanism of action: streptomycin
A. blocks reverse transcriptase
B. blocks protein synthesis
C. blocks RNA polymerase
D. blocks the topoisomerase enzyme
2.
Antimycobacterial agent NOT absorbed orally:
A. isoniazid (INH)
B. streptomycin
C. rifampin (Rimactane)
D. ethambutol (Myambutol)
3.Most significant antituberculosis drug:
A. rifampin (Rimactane)
B. saquinavir (Invirase)
C. isoniazid (INH)
D. streptomycin
4.NOT an appropriate use for rifampin (Rimactane):
A. treatment of leprosy (with a sulfone)
B. treatment of meningococcal carriers
C. prophylaxis for exposure to H. influenzae
D. Pseudomonal bacteriostasis
5.Following oral administration, blood brain barrier prevents effective treatment of CNS tuberculosis:
A. rifampin (Rimactane) to
B. ethambutol (Myambutol)
C. isoniazid (INH)
D. streptomycin
6.Mechanim of action: rifampin (Rimactane)
A. PABA competitor
B. mcolic acid synthesis
C. inhibits RNA synthesis by binding to DNA dependent RNA polymerase
D. none of the above
7."Fast and slow acetylators" influence this (these) drug's metabolism:
A. penicillin
B. sulfonamides
C. isoniazid (INH)
D. B & C
8.NOT a side effect of isoniazid (INH):
A. hepatotoxicity
B. allergic reactions
C. peripheral neuritis
D. nephrotoxicity
9.Isoniazid (INH)
A. tuberculostatic agent
B. neurotoxicity
C. well-absorbed from the GI tract
D. all of the above
10.Auditory deficits:
A. steptomycin
B. ethambutol (Myambutol)
C. both
D. neither
11.Liver toxicity (hepatoxic)
A. isoniazid (INH)
B. rifampin (Rimactane)
C. both
D. neither
12.Primary drugs for treating tuberculosis:
A. PAS
B. ethambutol (Myambutol)
C. rifampin (Rimactane)
D. all of the above
13.Aminoglycoside agent useful in management of tuberculosis
A. ethambutol (Myambutol)
B. streptomycin
C. isoniazid (INH)
D. cycloserine
14.Leprosy drug therapy:
A. dapsone
B. rifampin (Rimactane)
C. pyrimethamine (Daraprim)
D. all of the above
15.Hepatotoxic given at normal doses for extended periods for treatment of tuberculosis:
A. streptomycin
B. para-aminosalicylic acid (PAS)
C. isoniazid (INH)
D. B & C
16.Decreases likelihood of resistance to other antituberculosis drugs:
A. rifampin (Rimactane)
B. ethambutol (Myambutol)
C. streptomycin
D. isoniazid (INH)
17.Mechanism of Action:PAS (para-aminosalicyclic acid)
A. PABA competitor
B. protein synthesis inhibitor
C. DNA polymerase inhibitor
D. inhibitor of cell wall synthesis
18.Minimum treatment duration for active TB
A. one to three months
B. six to nine months
C. for life
D. five years
19.Mechanism of action: isoniazid (INH)
A. competitive inhibitor with PABA
B. mycolic acid synthesis inhibitor
C. inhibits RNA polymerase (binds to the polymerase.
D. blocks protein synthesis like chloramphenicol (Chloromycetin)
20.Ethambutol (Myambutol) (in combination with isoniazid (INH)) exhibits adverse effects especially directed to this organ:
A. hepatic toxicity
B. nephrotoxicity
C. ocular toxicity
D. splenic toxicity
Bookmarks